LGVN
Longeveron Inc.
There isn't enough reported data to score LGVN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LGVN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
LGVN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LGVN PE Valuation
LGVN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LGVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect LGVN's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LGVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$62.80 | +$35.42 |
| Q2 2024 | -$87.40 | +$7.82 |
| Q1 2024 | -$96.10 | -$0.88 |
| Q4 2023 | -$102.00 | -$11.78 |
| Q3 2023 | -$98.22 | -$7.93 |
| Q2 2023 | -$95.22 | -$4.93 |
| Q1 2023 | -$95.22 | -$5.93 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 164% for LGVN versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
LGVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $115K | -16% |
| Q2 2026 | $287K | -9.2% |
| Q1 2026 | $398K | +4.5% |
| Q4 2025 | $365K | -39% |
| Q3 2025 | $137K | -82% |
| Q2 2025 | $316K | -32% |
| Q1 2025 | $381K | -30% |
| Q4 2024 | $603K | +857% |
LGVN's revenue has slid since its 2020 peak: $115,000 last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6258% | -923 points |
| Q2 2026 | -2150% | -442 points |
| Q1 2026 | -1200% | +160 points |
| Q4 2025 | -1479% | -769 points |
| Q3 2025 | -5336% | -4734 points |
| Q2 2025 | -1708% | -960 points |
| Q1 2025 | -1360% | -614 points |
| Q4 2024 | -710% | +7925 points |
LGVN's operating margin was −6258% last quarter, down 922 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LGVN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LGVN on profitability, with a higher operating margin.
LGVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | +$2.4M |
| Q2 2026 | -$5.8M | -$2M |
| Q1 2026 | -$4.4M | +$354K |
| Q4 2025 | -$5.3M | -$1.9M |
| Q3 2025 | -$5.1M | -$1.8M |
| Q2 2025 | -$3.8M | +$1M |
| Q1 2025 | -$4.7M | -$1.6M |
| Q4 2024 | -$3.4M | +$775K |
LGVN has burned cash in almost every quarter: −$18M over the past year, against −$17M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LGVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
LGVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +159% | +400K shares |
| 1 year | +208% | +440K shares |
| 3 years | +243% | +461K shares |
LGVN has 650,988 diluted shares, up 208% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | $141,000 |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LGVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LGVN Net Leverage
LGVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LGVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.1 | Neutral |
| Stochastic | 11.1 | Oversold |
LGVN's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LGVN PE vs Healthcare Sector
LGVN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LGVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.16 | 38% above |
| 20 week MA | $4.85 | 39% below |
| 50 week MA | $6.35 | 53% below |
| 100 week MA | $9.53 | 69% below |
| 200 week MA | $83.3 | 96% below |
LGVN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 96% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LGVN on trend strength, trading above more of its moving averages.
LGVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $741.0 | $1,370.0 | +85% |
| 2022 | $1,370.0 | $327.0 | -76% |
| 2023 | $327.0 | $136.0 | -58% |
| 2024 | $136.0 | $17.5 | -87% |
| 2025 | $17.5 | $5.32 | -70% |
| 2026 YTD | $5.32 | $2.97 | -44% |
LGVN has finished four years in a row lower, and it's down 44% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LGVN on returns for 2026, with the stronger performance.